20 June 2018 - - North Chicago, Illinois-based global biopharmaceutical company AbbVie (NYSE: ABBV) has released investigational data from a new analysis of undetectable minimal residual disease (uMRD) rates from the phase 3 MURANO trial of venetoclax, a first-in-class oral B-cell lymphoma-2 (BCL-2) inhibitor, in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL), the company said.
The international, multicenter, open-label, randomized phase 3 MURANO study included a total of 389 patients with R/R CLL who had received at least one prior therapy.
The primary endpoint was progression-free survival of venetoclax in combination with rituximab for up to two years compared with bendamustine in combination with rituximab for six months.
Of the 121 patients who achieved uMRD at the end of combination therapy, 83% maintained uMRD and were progression-free for a median of 13.8 months thereafter.
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for complex and critical conditions.
The company's mission is to improve treatments across four primary therapeutic areas: immunology, oncology, virology, and neuroscience.